AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9591926 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 microg of a 2.8‐microm monodisperse ipratropium bromide aerosol
Number of subjects: 10
Study 9591926 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg from a metered‐dose inhaler plus spacer
Number of subjects: 10
Study 9591926 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 10
Study 7846921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. with preoperative cathartic (group OA, n = 159)
Number of subjects: 327
Study 7846921 — intervention group
Group type: COMPARATOR
Intervention: No oral antibiotic (group NOA, n = 168)
Number of subjects: 327
Study 3406688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia applied intraoperatively to the intercostal nerves
Number of subjects: 144
Study 3406688 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine‐adrenaline intercostal blockade
Number of subjects: 144
Study 30563365 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form intervention
Number of subjects: 112
Study 30563365 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 112
Study 29748350 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF) defined as a creatinine increase of ≥0.3 mg/dL
Number of subjects: 2033
Study 29748350 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 2033
Study 28376921 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based emotion-focused educational programme (4 sessions + 1 booster over 4 months)
Number of subjects: 198
Study 28376921 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (3 meetings over 4 months)
Number of subjects: 198
Study 26308169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oratane
Number of subjects: 0
Study 26308169 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian-sourced Roaccutane
Number of subjects: 0
Study 26308169 — intervention group
Group type: COMPARATOR
Intervention: Mexican-sourced Roaccutan
Number of subjects: 0
Study 23207892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster set (CS) with 30-second rest intervals
Number of subjects: 12
Study 23207892 — intervention group
Group type: COMPARATOR
Intervention: 5RM until failure
Number of subjects: 12
Study 23207892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster set (CS)
Number of subjects: 12
Study 20924294 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion morphine
Number of subjects: 120
Study 20924294 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion morphine with Bupivacaine
Number of subjects: 120
Study 20924294 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 120
Study 18420875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ultrasound and neurostimulation guidance (US-NS group)
Number of subjects: 60
Study 18420875 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation alone (NS group)
Number of subjects: 60
Study 15385274 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary case conferences
Number of subjects: 154
Study 15385274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case conferences)
Number of subjects: 154
Study 11733916 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent (group I)
Number of subjects: 44
Study 11733916 — intervention group
Group type: COMPARATOR
Intervention: Bladder catheterization (group II)
Number of subjects: 44
Study 9620818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mothers taught comforting and interacting techniques within 24 hours of delivery)
Number of subjects: 60
Study 9620818 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal scores in the intervention group
Number of subjects: 60
Study 9620818 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers not receiving the intervention)
Number of subjects: 60
Study 7802475 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic techniques (Marshall‐Marchetti‐Krantz and Burch)
Number of subjects: 31
Study 7802475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal techniques (Raz I and II)
Number of subjects: 31
Study 7802475 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension technique
Number of subjects: 31
Study 3162870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 10
Study 3162870 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10
Study 31571329 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX‐A) infiltration
Number of subjects: 50
Study 31571329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infiltration
Number of subjects: 50
Study 31571329 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) programme (12 sessions)
Number of subjects: 50
Study 28631250 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + probiotic (Lactobacillus salivarius NK02)
Number of subjects: 2
Study 28631250 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 2
Study 26837632 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated FP/HIV services (N = 12)
Number of subjects: 960
Study 26837632 — intervention group
Group type: COMPARATOR
Intervention: Standard referral for FP (N = 6)
Number of subjects: 960
Study 25255021 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope with CPR
Number of subjects: 30
Study 25255021 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope with CPR
Number of subjects: 30
Study 25255021 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope without CPR
Number of subjects: 30
Study 25255021 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope without CPR
Number of subjects: 30
Study 25255021 — intervention group
Group type: COMPARATOR
Intervention: Truview EVO2 vs Macintosh laryngoscope in CPR scenario
Number of subjects: 30
Study 25255021 — intervention group
Group type: COMPARATOR
Intervention: Truview EVO2 vs Macintosh laryngoscope in no-CPR scenario
Number of subjects: 30
Study 25255021 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30
Study 25255021 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope
Number of subjects: 30
Study 22651880 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EESs)
Number of subjects: 3687
Study 22651880 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 3687
Study 20386463 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLFIG chemoimmunotherapy (gemcitabine, oxaliplatin, 5‐fluorouracil/folinic acid, granulocyte macrophage colony‐stimulating factor, and aldesleukine)
Number of subjects: 57
Study 20386463 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg high score
Number of subjects: 57
Study 18356602 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital HIV-neutralizing IgA
Number of subjects: 113
Study 18356602 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-specific proliferation
Number of subjects: 113
Study 18356602 — intervention group
Group type: COMPARATOR
Intervention: HIV-specific IFNgamma production
Number of subjects: 113
Study 18356602 — intervention group
Group type: COMPARATOR
Intervention: Genital herpes (HSV2)
Number of subjects: 113
Study 16051499 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold therapy with 30% load
Number of subjects: 14
Study 11518831 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group A, 4 IU/m(2)/d
Number of subjects: 68
Study 11518831 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group B, first year 4 IU/m(2)/d, thereafter 6 IU/m(2)/d
Number of subjects: 68
Study 11518831 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dosage group C, first year 4 IU/m(2)/d, second year 6 IU/m(2)/d, thereafter 8 IU/m(2)/d
Number of subjects: 68
Study 11518831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 68
Study 9625091 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (20-35 g)
Number of subjects: 51
Study 9625091 — intervention group
Group type: COMPARATOR
Intervention: Placebo triacylglycerol
Number of subjects: 51
Study 7933659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg IPA-E
Number of subjects: 34
Study 7933659 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg IPA-E
Number of subjects: 34
Study 7933659 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-administration values)
Number of subjects: 34
Study 2463717 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg metoprolol per day
Number of subjects: 13
Study 2463717 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol per day
Number of subjects: 13
Study 2463717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30141180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (0.25 mg/kg)
Number of subjects: 12
Study 28346377 — intervention group
Group type: EXPERIMENTAL
Intervention: Beamforming transmission (randomized beamforming and center-directed)
Number of subjects: 0
Study 28346377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UCA and randomized beamforming scheme
Number of subjects: 0
Study 28346377 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of antenna elements and degree of path loss
Number of subjects: 0
Study 28346377 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional antennas
Number of subjects: 0
Study 25502081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 120
Study 25502081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23515464 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive recruitment method (referred in person by oncologist)
Number of subjects: 0
Study 23515464 — intervention group
Group type: COMPARATOR
Intervention: Reactive recruitment method (letters mailed through oncologist's office)
Number of subjects: 0
Study 21465778 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural resonance electromagnetotherapy (SRT)
Number of subjects: 0
Study 19451573 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom‐made neoprene splint
Number of subjects: 112
Study 19451573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 16423666 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial performance index (MPI) of 0.50 or higher
Number of subjects: 512
Study 16423666 — intervention group
Group type: COMPARATOR
Intervention: Baseline MPI less than 0.50
Number of subjects: 512
Study 15567053 — intervention group
Group type: EXPERIMENTAL
Intervention: TFL-assisted treatment group
Number of subjects: 50
Study 15567053 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment group
Number of subjects: 50
Study 11763512 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisekvens
Number of subjects: 60
Study 11763512 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisekvens plus betaksolol (10‐20 mg/day)
Number of subjects: 60
Study 11763512 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaksolol
Number of subjects: 60
Study 9209440 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 4
Study 9209440 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 4
Study 7965451 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil source of docosahexaenoic acid
Number of subjects: 0
Study 7965451 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 0
Study 30850453 — intervention group
Group type: EXPERIMENTAL
Intervention: Five Wishes
Number of subjects: 2748
Study 30850453 — intervention group
Group type: COMPARATOR
Intervention: Oklahoma Advance Directive (OKAD)
Number of subjects: 2748
Study 30477210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral health instruction at baseline and self-assessment every three months
Number of subjects: 0
Study 30477210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral health instruction
Number of subjects: 0
Study 30477210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 27345158 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (1 mg estradiol and 0.5 mg norethisterone acetate)
Number of subjects: 50
Study 27345158 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (2.5 mg)
Number of subjects: 50
Study 25208233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 1184
Study 25208233 — intervention group
Group type: COMPARATOR
Intervention: Usual care (neostigmine or spontaneous recovery)
Number of subjects: 1184
Study 22608582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ketamine
Number of subjects: 192
Study 22608582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine
Number of subjects: 192
Study 22608582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 192
Study 19995467 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated Prevention Programme for Externalizing Problem behaviour (PEP)
Number of subjects: 155
Study 19995467 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 155
Study 18160677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive interviews
Number of subjects: 1058
Study 18160677 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1058
Study 18160677 — intervention group
Group type: COMPARATOR
Intervention: ACASI
Number of subjects: 1058
Study 16888464 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (approximately 32% VO2max)
Number of subjects: 9
Study 12794019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m)
Number of subjects: 12
Study 12794019 — intervention group
Group type: COMPARATOR
Intervention: Filtered [(99m)Tc]sulfur colloid (fTcSC) (.2 micro m)
Number of subjects: 12
Study 12794019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Number of subjects: 12
Study 12794019 — intervention group
Group type: COMPARATOR
Intervention: fTcSC
Number of subjects: 12
Study 10801082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 2% MVC
Number of subjects: 8
Study 10801082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 5% MVC
Number of subjects: 8
Study 10801082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 10% MVC
Number of subjects: 8
Study 10801082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 20% MVC
Number of subjects: 8
Study 10801082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 30% MVC
Number of subjects: 8
Study 10801082 — intervention group
Group type: COMPARATOR
Intervention: Sham trials (no active pull)
Number of subjects: 8
Study 9251452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP) added peritoneal dialysis (PD) with 36 cycles of intermittent PD, exchange volume of 1 litre, duration of 1 hour per cycle, SNP dose of 4 mg/litre in alternate clearance periods.
Number of subjects: 30
Study 9251452 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (HD) for 4 hours.
Number of subjects: 30
Study 1735861 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm incision with implantation of an Allergan Medical Optics three‐piece SI‐18NB silicone lens
Number of subjects: 112
Study 1735861 — intervention group
Group type: COMPARATOR
Intervention: 6.0 mm incision with implantation of a three‐piece biconvex poly(methyl methacrylate) lens
Number of subjects: 112
Study 1735861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 6698337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 patients)
Number of subjects: 19
Study 6698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (7 patients)
Number of subjects: 19
Study 6698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (7 patients)
Number of subjects: 19
Study 6698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (2 g per day for one week)
Number of subjects: 19
Study 6698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin vs. Lysine acetylsalicylate
Number of subjects: 19
Study 6698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 19
Study 31619260 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term prophylaxis strategy
Number of subjects: 0
Study 29233060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeals intervention
Number of subjects: 0
Study 29233060 — intervention group
Group type: COMPARATOR
Intervention: Non-threatening intervention
Number of subjects: 0
Study 27663627 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate glasses
Number of subjects: 117
Study 27663627 — intervention group
Group type: COMPARATOR
Intervention: Observation and glasses if deterioration occurred
Number of subjects: 117
Study 24193227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 61
Study 24193227 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 61
Study 22160514 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle technique
Number of subjects: 84
Study 22160514 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle technique
Number of subjects: 84
Study 22160514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 84
Study 19158208 — intervention group
Group type: EXPERIMENTAL
Intervention: Total quantified flavonoid intake (quercetin, kaempferol, myricetin, apigenin, luteolin)
Number of subjects: 38408
Study 19158208 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich foods (tea, apple, broccoli, onion, tofu)
Number of subjects: 38408
Study 17846548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus augmentation with 100% autologous bone
Number of subjects: 24
Study 17846548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus augmentation with 100% Bio‐Oss
Number of subjects: 24
Study 17846548 — intervention group
Group type: COMPARATOR
Intervention: Control (preexisting subantral bone)
Number of subjects: 24
Study 14963469 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic ED group (n=23)
Number of subjects: 46
Study 14963469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasculogenic ED group (n=23)
Number of subjects: 46
Study 14963469 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 46
Study 14963469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasculogenic ED with arterial risk factors
Number of subjects: 46
Study 14963469 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients achieving full erection at pharmacological test
Number of subjects: 46
Study 14963469 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with bioavailable testosterone levels
Number of subjects: 46
Study 14963469 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with DHEA-S levels
Number of subjects: 46
Study 11779741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral jaw-positioning appliance (6-month trial)
Number of subjects: 32
Study 11779741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 9678813 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. and tinidazole 500 mg b.d. (group RBCCT)
Number of subjects: 70
Study 9678813 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. plus amoxycillin 1 g b.d. (group RBCCA)
Number of subjects: 70
Study 7862890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine injections (0.6 mg, subcutaneous, two injections 40 min apart)
Number of subjects: 4
Study 7862890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 2777568 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS-course A (hospital-wide Heartsaver course)
Number of subjects: 90
Study 2777568 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS-course C (Basic Cardiac Life Support course)
Number of subjects: 90
Study 1239491 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (frustration with difficult puzzle)
Number of subjects: 44
Study 1239491 — intervention group
Group type: COMPARATOR
Intervention: Control group (easier task)
Number of subjects: 44
Study 1239491 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (frustration)
Number of subjects: 44
Study 31533016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit condition
Number of subjects: 0
Study 31533016 — intervention group
Group type: COMPARATOR
Intervention: Fixation condition
Number of subjects: 0
Study 28540893 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration with profiled potassium (AFBK)
Number of subjects: 10
Study 28540893 — intervention group
Group type: COMPARATOR
Intervention: Online hemodiafiltration (olHDF)
Number of subjects: 10
Study 25988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention delivered by community pharmacists (n=205)
Number of subjects: 407
Study 25988589 — intervention group
Group type: COMPARATOR
Intervention: Leaflet-only control condition (n=202)
Number of subjects: 407
Study 25988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (n=205)
Number of subjects: 407
Study 23085213 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based physiotherapeutic exercise programme
Number of subjects: 0
Study 23085213 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21451937 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 sets of squat exercise at 80% of 1-RM
Number of subjects: 32
Study 21451937 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 sets of squat exercise at 80% of 1-RM
Number of subjects: 32
Study 21451937 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set of squat exercise at 80% of 1-RM
Number of subjects: 32
Study 21451937 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 4, and 8 sets)
Number of subjects: 32